JP7483684B2 - 急性肺損傷の処置のための組成物および方法 - Google Patents

急性肺損傷の処置のための組成物および方法 Download PDF

Info

Publication number
JP7483684B2
JP7483684B2 JP2021507917A JP2021507917A JP7483684B2 JP 7483684 B2 JP7483684 B2 JP 7483684B2 JP 2021507917 A JP2021507917 A JP 2021507917A JP 2021507917 A JP2021507917 A JP 2021507917A JP 7483684 B2 JP7483684 B2 JP 7483684B2
Authority
JP
Japan
Prior art keywords
pip
lps
polypeptide
present
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021507917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534184A (ja
JP2021534184A5 (cg-RX-API-DMAC7.html
Inventor
アーロン ビー. フィッシャー
シェルドン アイ. フェインステイン
Original Assignee
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア filed Critical ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Publication of JP2021534184A publication Critical patent/JP2021534184A/ja
Publication of JP2021534184A5 publication Critical patent/JP2021534184A5/ja
Priority to JP2024074284A priority Critical patent/JP7822065B2/ja
Application granted granted Critical
Publication of JP7483684B2 publication Critical patent/JP7483684B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021507917A 2018-08-17 2019-08-15 急性肺損傷の処置のための組成物および方法 Active JP7483684B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024074284A JP7822065B2 (ja) 2018-08-17 2024-05-01 急性肺損傷の処置のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719217P 2018-08-17 2018-08-17
US62/719,217 2018-08-17
PCT/US2019/046698 WO2020037146A1 (en) 2018-08-17 2019-08-15 Compositions and methods for treatment of acute lung injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024074284A Division JP7822065B2 (ja) 2018-08-17 2024-05-01 急性肺損傷の処置のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2021534184A JP2021534184A (ja) 2021-12-09
JP2021534184A5 JP2021534184A5 (cg-RX-API-DMAC7.html) 2022-08-19
JP7483684B2 true JP7483684B2 (ja) 2024-05-15

Family

ID=69524874

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021507917A Active JP7483684B2 (ja) 2018-08-17 2019-08-15 急性肺損傷の処置のための組成物および方法
JP2024074284A Active JP7822065B2 (ja) 2018-08-17 2024-05-01 急性肺損傷の処置のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024074284A Active JP7822065B2 (ja) 2018-08-17 2024-05-01 急性肺損傷の処置のための組成物および方法

Country Status (11)

Country Link
US (2) US12070483B2 (cg-RX-API-DMAC7.html)
EP (1) EP3836953A4 (cg-RX-API-DMAC7.html)
JP (2) JP7483684B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210046698A (cg-RX-API-DMAC7.html)
CN (1) CN112703009B (cg-RX-API-DMAC7.html)
AU (1) AU2019321654B8 (cg-RX-API-DMAC7.html)
BR (1) BR112021002920A2 (cg-RX-API-DMAC7.html)
CA (1) CA3109798A1 (cg-RX-API-DMAC7.html)
IL (1) IL280868B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021001877A (cg-RX-API-DMAC7.html)
WO (1) WO2020037146A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112703009B (zh) 2018-08-17 2024-06-11 宾夕法尼亚大学董事会 治疗急性肺损伤的组合物和方法
KR20260034620A (ko) * 2023-05-05 2026-03-11 페록시테크 인코포레이티드. 패혈성 쇼크 치료용 조성물 및 방법
EP4720090A1 (en) * 2023-05-26 2026-04-08 The Trustees of The University of Pennsylvania Protective agent against endothelial dysfunction

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006301A2 (en) 2000-06-30 2002-01-24 University Of Cincinnati Peptides with antioxidant and antimicrobial properties

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
CA2132012C (en) 1992-03-25 2003-04-22 John W. Shell Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
WO2002096404A1 (en) 2001-05-29 2002-12-05 Depomed Development Ltd Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
NZ536796A (en) * 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
EP1764095A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
WO2011157819A2 (en) * 2010-06-18 2011-12-22 Xiberscience Gmbh Peptides as active agents to stabilize biological barriers
US8962570B2 (en) * 2011-05-17 2015-02-24 University of Pittsburgh—of the Commonwealth System of Higher Education Therapeutic use of peptide inhibitors of NADPH oxidase; aerosolization as a delivery mechanism
US11110152B2 (en) * 2016-04-11 2021-09-07 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing lung disease
CN112703009B (zh) 2018-08-17 2024-06-11 宾夕法尼亚大学董事会 治疗急性肺损伤的组合物和方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006301A2 (en) 2000-06-30 2002-01-24 University Of Cincinnati Peptides with antioxidant and antimicrobial properties

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FISHER A. B. et al.,Antioxidants,2018年12月05日,7, 181,pp.1-13
FISHER A. B. et al.,Int. J. Mol. Sci.,2019年05月15日,20, 2395,pp.1-16
KRISHNAIAH S. et al.,Biochim Biophys Acta.,2016年,1864(4),pp.419-425

Also Published As

Publication number Publication date
JP7822065B2 (ja) 2026-03-02
MX2021001877A (es) 2021-07-15
US20250082715A1 (en) 2025-03-13
US20210315964A1 (en) 2021-10-14
BR112021002920A2 (pt) 2021-05-11
EP3836953A4 (en) 2022-06-29
EP3836953A1 (en) 2021-06-23
IL280868B1 (en) 2026-05-01
JP2024102207A (ja) 2024-07-30
AU2019321654A1 (en) 2021-03-18
JP2021534184A (ja) 2021-12-09
IL280868A (en) 2021-04-29
AU2019321654B1 (en) 2025-07-17
KR20210046698A (ko) 2021-04-28
US12070483B2 (en) 2024-08-27
AU2019321654B8 (en) 2025-08-07
WO2020037146A1 (en) 2020-02-20
CA3109798A1 (en) 2020-02-20
CN112703009B (zh) 2024-06-11
CN112703009A (zh) 2021-04-23

Similar Documents

Publication Publication Date Title
JP7822065B2 (ja) 急性肺損傷の処置のための組成物および方法
Geller Aerosol antibiotics in cystic fibrosis
EP3528820B1 (en) Novel pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases
KR102480800B1 (ko) 엘라스타제 억제 활성을 갖는 베타-헤어핀 펩티드 모방체 및 이의 에어로졸 투여 형태
US20230050861A1 (en) Compositions and methods for treating pulmonary edema or lung inflammation
RU2817906C2 (ru) Композиции и способы лечения острого повреждения легких
US12569459B2 (en) Compositions and methods for treating pulmonary edema or lung inflammation
HK40013569A (en) Novel pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases
HK40013569B (en) Novel pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases
KR20260034620A (ko) 패혈성 쇼크 치료용 조성물 및 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230915

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240306

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240501

R150 Certificate of patent or registration of utility model

Ref document number: 7483684

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150